TickerFacts.

Compare

Jasper Therapeutics, Inc. vs Inmune Bio, Inc. vs IN8BIO, Inc. vs Viskase Holdings, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearJasper Therapeutics, Inc.
JSPR		Inmune Bio, Inc.
INMB		IN8BIO, Inc.
INAB		Viskase Holdings, Inc.
VISKRevenue covers only part of its income (partial revenue)
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$50.0Kn/an/a
Revenue growth (YoY)n/a+257.1%n/an/a
Gross marginn/an/an/an/a
Operating marginn/an/mn/an/a
Net marginn/an/mn/an/a
Net income-$75.80M-$45.93M-$19.44M-$3.41M
EPS (Diluted)-$3.95-$1.86-$4.44-$0.07
Operating cash flow-$77.16M-$22.58M-$12.71M-$3.01M
Free cash flown/a-$23.62Mn/an/a
Cash & equivalents$28.69M$24.75Mn/a$42.57M
Total assets$35.78M$32.35M$32.28M$42.81M
Total liabilities$31.63M$8.83M$4.72Mn/a
Shareholders' equity$4.15M$23.52M$27.56M-$2.52M
Return on year-end equityn/m-195.3%-70.5%n/a
Shares outstanding28.00M26.59M9.77M74.21M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearJasper Therapeutics, Inc.Inmune Bio, Inc.IN8BIO, Inc.Viskase Holdings, Inc.
Latestn/a$50.0K
Ended 2025-12-31		n/an/a
1 year earliern/a$14.0K
Ended 2024-12-31		n/an/a
2 years earliern/a$155.0K
Ended 2023-12-31		n/an/a
3 years earliern/a$374.0K
Ended 2022-12-31		n/an/a
4 years earliern/a$181.0K
Ended 2021-12-31		n/an/a